SUMMARY The evolution of prostate cancer from an androgen-dependent state (ADPCa) to one that is androgen-independent (AIPCa) marks its lethal progression. The androgen receptor (AR) is essential in both, though its function in AIPCa is poorly understood. We have defined the direct AR-dependent target genes in both AIPCa and ADPCa by generating AR-dependent gene expression profiles and AR cistromes. In contrast to ADPCa, AR selectively up-regulates M-phase cell cycle genes in AIPCa including UBE2C, a gene that inactivates the M-phase checkpoint. Selective epigenetic marks and collaborating transcription factor occupancy at UBE2C enhancers leads to increased AR recruitment and UBE2C over-expression in AIPCa cell lines and clinical cases. Silencing of UBE2C blocks AIPCa but not ADPCa growth. Thus the role of AR in AIPCa is not to direct the androgen-dependent gene expression program without androgen, but rather to execute a distinct program resulting in androgen-independent growth.

The histone modification state of genomic regions is hypothesized to reflect the regulatory activity of the underlying genomic DNA. Based on this hypothesis, the ENCODE Project Consortium measured the status of multiple histone modifications across the genome in several cell types and used these data to segment the genome into regions with different predicted regulatory activities. We measured the cis-regulatory activity of more than 2000 of these predictions in the K562 leukemia cell line. We tested genomic segments predicted to be Enhancers, Weak Enhancers, or Repressed elements in K562 cells, along with other sequences predicted to be Enhancers specific to the H1 human embryonic stem cell line (H1-hESC). Both Enhancer and Weak Enhancer sequences in K562 cells were more active than negative controls, although surprisingly, Weak Enhancer segmentations drove expression higher than did Enhancer segmentations. Lower levels of the covalent histone modifications H3K36me3 and H3K27ac, thought to mark active enhancers and transcribed gene bodies, associate with higher expression and partly explain the higher activity of Weak Enhancers over Enhancer predictions. While DNase I hypersensitivity (HS) is a good predictor of active sequences in our assay, transcription factor (TF) binding models need to be included in order to accurately identify highly expressed sequences. Overall, our results show that a significant fraction (~26%) of the ENCODE enhancer predictions have regulatory activity, suggesting that histone modification states can reflect the cis-regulatory activity of sequences in the genome, but that specific sequence preferences, such as TF-binding sites, are the causal determinants of cis-regulatory activity.[Supplemental material is available for this article.]It is widely reported that specific combinations of covalent histone modifications reflect the regulatory function of underlying genomic DNA sequence (Strahl and Allis 2000). As part of the ENCODE Project, the genomic locations of a variety of covalent histone modifications were determined by chromatin immunoprecipitation sequencing (ChIP-seq) in a number of cell types and cell lines. Two studies used these data to train computational models that predict different functional regions of the human genome. These unsupervised learning algorithms, Segway (Hoffman et al. 2012) and ChromHMM Kellis 2010, 2012), take functional genomics data as input (DNase-seq; FAIRE-seq; and ChIP-seq of histone modifications, RNA polymerase II large subunit [POLR2A], and CTCF) and return segmentation classes, which are then assigned a hypothesized function using current knowledge of histone modification function. As part of the ENCODE Project, these two sets of predictions were consolidated to create a unified annotation of the entire human genome with seven functional classes in multiple cell types. These segmentations include Transcription Start Site, Promoter Flanking, Transcribed, CTCF-bound, Enhancer, Weak Enhancer, and Repressed or Inactive segments (The ENCODE Project ...

These observations suggest that FASN can act as a prostate cancer oncogene in the presence of AR and that FASN exerts its oncogenic effect by inhibiting the intrinsic pathway of apoptosis.